Pfizer Research Grant: Improving Health Outcomes in Patients with ATTR-CM

Support for medical societies or professional organizations, in partnership with patient advocacy organizations, to develop, validate, and evaluate a shared decision-making tool aimed at improving decision quality, health outcomes, and patient experience for individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Overview

• Funding: Up to $250,000 USD per project (includes direct costs, institutional overhead capped at 28%, and indirect costs)
• Maximum project duration: 1 year 
• Geographic scope: United States only 
• Required collaboration: Medical societies/professional organizations must partner with patient advocacy organizations 
• Milestone-based payment structure with 6 deliverable checkpoints throughout project
• Publication expected in peer-reviewed journal and online distribution

Priority Areas

• Tool Design & Methodology: "Tool design and content development consistent with decision-making theory and methodology for SDM tool development and validation"
• Stakeholder Co-Development: "Co-development of the tool with stakeholders to ensure relevance, clarity, and acceptability" including patients with ATTR-CM, patient advocacy organizations, caregivers, cardiac amyloidosis specialists, cardiologists, nurses, and allied HCPs 
• Needs Assessment: "Needs assessment and conceptual framework grounded in bidirectional information exchange including literature review and focus groups with stakeholders to identify gaps and decision-making challenges in ATTR-CM care pathway" 
• Validation & Usability: "Assessment of the tool including tool validity and usability testing with end-users for practical real-world clinical use and minimization of unintended barriers to engagement" 

Eligibility & Requirements

• Applicant must be medical society or professional organization that includes ATTR-CM as a focus area, in partnership with patient advocacy organization 
• Institution and Principal Investigator must be based in the United States
• Only organizations are eligible (not individuals or medical practice groups)
  PI must hold MD, PhD, or equivalent; advanced nursing degree (BSN with MS/PhD); or degree in Pharmacy, Physiotherapy, or Social Work
• PI must be employee or contractor of requesting organization 
• Organization must be legally able to receive funding directly from Pfizer Inc. 
• For multi-institutional projects, all institutions must have relevant role and requesting organization must have key role 
• Proposals must address ALL specified areas of interest (tool design, co-development, needs assessment, validation) 
• Proposals requesting drug compounds (investigational or approved) are out of scope and will not be reviewed
• Applications submitted after deadline will not be reviewed 
• Project cannot have already commenced prior to Pfizer support 

Timeline

• RFP Release: March 10, 2026
• Submission Deadline: May 5, 2026 (23:59 EST) 
• Anticipated Award Notification: June 19, 2026
• Anticipated Project Start: September 2026
• Milestone 1 (20% - $50,000): Project initiation with draft kickoff agenda, timeline, and first draft wireframe
• Milestone 2 (10% - $25,000): Successful recruitment and onboarding of patient advocacy group 
• Milestone 3 (20% - $50,000): Receipt of draft version 1 co-created with patients using IPDAS criteria 
• Milestone 4 (20% - $50,000): Receipt of internal validation outputs compared to standard SDM validation instrument
• Milestone 5 (20% - $50,000): Delivery of final SDM tool co-created with and approved by patient advocacy organization 
• Milestone 6 (10% - $25,000): Receipt of notification of project submission to peer-reviewed journal 
• Anticipated Project End: September 2027 

How to Submit

• Access the online portal at www.cybergrants.com/pfizer/Research and sign in 
• First-time users must click "Create your password" 
• Click "Start A New Research Grant Application" button
• Complete all required sections of the online application 
• Prepare proposal document: single-spaced, Calibri 12-point font, 1-inch margins, 15-page limit (exclusive of references)
• Proposal must address: Goals and Objectives, Assessment of Need, Target Audience, Project Design and Methods, Innovation, Evaluation and Outcomes, Anticipated Timeline, Additional Information (including mentor letters for early-career applicants), Organization Detail, and Budget Detail 
• Upload complete proposal in the Proposal/Protocol field 
• Select "Yes" for question "Competitive Grant?" 
• Select Primary Area of Interest: CVM - ATTR-CM (Transthyretin Amyloid Cardiomyopathy) - RES 
• Select Competitive Grant Program Name: 2026 RD US CVM ATTR-CM SDM RES [Page 3]
• For questions, contact Grant Officer Talita Honorato-Rzeszewicz at talita.honorato-rzeszewicz@pfizer.com with subject line "2026 RD US Rare Cardio SDM" 
   

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.